NCE-1 Intelligence & Market Opportunity

Ohtuvayre

Ensifentrine

Respiratory Agents

Suspension; Inhalation

Ohtuvayre is an inhaled medication for adults with moderate to severe COPD, offering a new option beyond traditional steroids and bronchodilators. It targets two enzymes (PDE3 and PDE4) to both open airways and reduce lung inflammation

Approval Date

26-Jun-24

NCE-1 Date

26-Jun-28

NCE Date

26-Jun-29

Commercial snapshot

Market performance & projections

Revenue ($M)

178

CAGR (%)

0.829

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

853

2027

1252

2028

1605

2029

1992

2030

2377

2031

2737

2032

2995

Molecule profile

Details & specifications

Molecule

Ensifentrine

Innovator

VERONA PHARMA INC

Dosage Form

Suspension; Inhalation

Strength

3 mg/2.5 mL

Therapeutic Category

Respiratory Agents

Usage

To treat chronic obstructive pulmonary disease

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.